vs

Side-by-side financial comparison of BEYOND MEAT, INC. (BYND) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

BEYOND MEAT, INC. is the larger business by last-quarter revenue ($61.6M vs $35.5M, roughly 1.7× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -19.7%). RECURSION PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-47.3M vs $-49.8M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -9.7%).

Beyond Meat, Inc., branded as Beyond, is a producer of plant-based meat alternatives founded in 2009 by Ethan Brown. The company's products were first launched in the United States in 2012.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BYND vs RXRX — Head-to-Head

Bigger by revenue
BYND
BYND
1.7× larger
BYND
$61.6M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+701.4% gap
RXRX
681.7%
-19.7%
BYND
More free cash flow
RXRX
RXRX
$2.5M more FCF
RXRX
$-47.3M
$-49.8M
BYND
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-9.7%
BYND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BYND
BYND
RXRX
RXRX
Revenue
$61.6M
$35.5M
Net Profit
$-108.1M
Gross Margin
-11.5%
59.8%
Operating Margin
-211.4%
-304.8%
Net Margin
-304.2%
Revenue YoY
-19.7%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.68
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BYND
BYND
RXRX
RXRX
Q4 25
$61.6M
$35.5M
Q3 25
$70.2M
$5.2M
Q2 25
$75.0M
$19.2M
Q1 25
$68.7M
$14.7M
Q4 24
$76.7M
$4.5M
Q3 24
$81.0M
$26.1M
Q2 24
$93.2M
$14.4M
Q1 24
$75.6M
$13.8M
Net Profit
BYND
BYND
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-110.7M
$-162.3M
Q2 25
$-29.2M
$-171.9M
Q1 25
$-52.9M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-26.6M
$-95.8M
Q2 24
$-34.5M
$-97.5M
Q1 24
$-54.4M
$-91.4M
Gross Margin
BYND
BYND
RXRX
RXRX
Q4 25
-11.5%
59.8%
Q3 25
10.3%
-183.8%
Q2 25
11.5%
-4.9%
Q1 25
-1.5%
-48.0%
Q4 24
13.1%
-181.4%
Q3 24
17.7%
53.7%
Q2 24
14.7%
36.2%
Q1 24
4.9%
19.1%
Operating Margin
BYND
BYND
RXRX
RXRX
Q4 25
-211.4%
-304.8%
Q3 25
-160.0%
-3327.6%
Q2 25
-46.6%
-916.8%
Q1 25
-81.8%
-1297.9%
Q4 24
-49.3%
-4042.4%
Q3 24
-38.2%
-377.1%
Q2 24
-36.4%
-697.4%
Q1 24
-70.7%
-698.4%
Net Margin
BYND
BYND
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-157.6%
-3135.3%
Q2 25
-39.0%
-894.2%
Q1 25
-77.0%
-1373.3%
Q4 24
-3935.5%
Q3 24
-32.8%
-367.5%
Q2 24
-37.0%
-676.6%
Q1 24
-71.9%
-662.4%
EPS (diluted)
BYND
BYND
RXRX
RXRX
Q4 25
$0.68
$-0.17
Q3 25
$-1.44
$-0.36
Q2 25
$-0.38
$-0.41
Q1 25
$-0.69
$-0.50
Q4 24
$-0.65
$-0.56
Q3 24
$-0.41
$-0.34
Q2 24
$-0.53
$-0.40
Q1 24
$-0.84
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BYND
BYND
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$203.9M
$743.3M
Total DebtLower is stronger
$415.7M
$9.6M
Stockholders' EquityBook value
$-997.0K
$1.1B
Total Assets
$614.7M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BYND
BYND
RXRX
RXRX
Q4 25
$203.9M
$743.3M
Q3 25
$117.3M
$659.8M
Q2 25
$103.5M
$525.1M
Q1 25
$102.1M
$500.5M
Q4 24
$131.9M
$594.4M
Q3 24
$121.7M
$427.6M
Q2 24
$144.9M
$474.3M
Q1 24
$157.9M
$296.3M
Total Debt
BYND
BYND
RXRX
RXRX
Q4 25
$415.7M
$9.6M
Q3 25
$1.2B
$11.9M
Q2 25
$1.2B
$14.2M
Q1 25
$1.1B
$16.4M
Q4 24
$1.1B
$19.0M
Q3 24
$1.1B
$20.5M
Q2 24
$1.1B
$22.9M
Q1 24
$1.1B
Stockholders' Equity
BYND
BYND
RXRX
RXRX
Q4 25
$-997.0K
$1.1B
Q3 25
$-784.1M
$1.0B
Q2 25
$-677.0M
$919.1M
Q1 25
$-649.5M
$933.9M
Q4 24
$-601.2M
$1.0B
Q3 24
$-611.9M
$524.6M
Q2 24
$-590.0M
$584.4M
Q1 24
$-561.4M
$401.2M
Total Assets
BYND
BYND
RXRX
RXRX
Q4 25
$614.7M
$1.5B
Q3 25
$599.7M
$1.4B
Q2 25
$691.7M
$1.3B
Q1 25
$643.8M
$1.3B
Q4 24
$678.1M
$1.4B
Q3 24
$692.9M
$726.5M
Q2 24
$711.2M
$775.9M
Q1 24
$735.0M
$557.8M
Debt / Equity
BYND
BYND
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BYND
BYND
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.8M
$-46.1M
Free Cash FlowOCF − Capex
$-49.8M
$-47.3M
FCF MarginFCF / Revenue
-80.8%
-133.1%
Capex IntensityCapex / Revenue
4.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-157.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BYND
BYND
RXRX
RXRX
Q4 25
$-46.8M
$-46.1M
Q3 25
$-38.8M
$-117.4M
Q2 25
$-33.2M
$-76.4M
Q1 25
$-26.1M
$-132.0M
Q4 24
$-29.0M
$-115.4M
Q3 24
$-22.0M
$-59.2M
Q2 24
$-16.0M
$-82.2M
Q1 24
$-31.8M
$-102.3M
Free Cash Flow
BYND
BYND
RXRX
RXRX
Q4 25
$-49.8M
$-47.3M
Q3 25
$-41.7M
$-117.6M
Q2 25
$-35.1M
$-79.6M
Q1 25
$-30.6M
$-133.8M
Q4 24
$-35.4M
$-116.7M
Q3 24
$-24.1M
$-63.8M
Q2 24
$-17.3M
$-83.4M
Q1 24
$-33.0M
$-109.0M
FCF Margin
BYND
BYND
RXRX
RXRX
Q4 25
-80.8%
-133.1%
Q3 25
-59.4%
-2272.5%
Q2 25
-46.9%
-413.9%
Q1 25
-44.6%
-907.4%
Q4 24
-46.2%
-2567.7%
Q3 24
-29.7%
-244.6%
Q2 24
-18.6%
-578.5%
Q1 24
-43.7%
-789.9%
Capex Intensity
BYND
BYND
RXRX
RXRX
Q4 25
4.8%
3.5%
Q3 25
4.1%
4.7%
Q2 25
2.6%
16.4%
Q1 25
6.5%
12.4%
Q4 24
8.4%
28.6%
Q3 24
2.5%
17.5%
Q2 24
1.4%
8.2%
Q1 24
1.6%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons